Effects of sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the presence and absence of diabetes mellitus in mice
Further studies revealed that GLP-1 agonists slowed or stopped stomach motility, causing blockages in the gastrointestinal tract
Therefore, in patients where the fasting glucose is a more dominant feature of their hyperglycemia, metformin may be more appropriate, while GLP-1RAs could be better suited for those with postprandial hyperglycemia
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)
doi: 10.1055/s-0033-1358678
Il nuovo studio ha rilevato un tasso di abbandono del farmaco simile a quello osservato nel Regno Unito: dopo 12 mesi dall'inizio della terapia, il 47% dei pazienti aveva smesso di prendere il GLP-1 AR, mentre dopo 24 mesi la percentuale saliva al 70%